Treatment of Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain

Official Title: “Efficacy of Three Treatment Modalities for Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain”

The purpose of this study is to assess the impact of three different treatment modalities on panic symptoms, quality of life and use of health services among individuals consulting an emergency department for non cardiac chest pain and having Panic Disorder.

Intervention(s) in this Clinical Trial

• Behavioral: Brief cognitive-behavioral treatment for Panic Disorder
  • One two-hour session of cognitive-behavior therapy for panic disorder
• Behavioral: Cognitive-Behavior Therapy for Panic Disorder
  • Seven one-hour sessions of cognitive-behavior therapy for panic disorder
• Drug: paroxetine
  • 40 mg die, for 6 months

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: 1
• Active Comparator: 2
• Active Comparator: 3
• No Intervention: 4

Primary Measures

• Panic Disorder diagnosis
  • Time Frame: Pre and posttreatment, and 3, 6 and 12 months after treament
    Safety Issue?: No

Secondary Measures

• Panic symptomatology, psychological distress, quality of life, and use of health services
  • Time Frame: Pre and posttreatment, and 3, 6 and 12 months after treatment
    Safety Issue?: No

Inclusion Criteria:

• Aged 18 and over
• Mastered oral and written French
• Consulted an emergency department for chest pain with very low risk of coronary disease (normal ECG and blood tests)
• Met criteria for Panic Disorder

Exclusion Criteria:

• Chest pain with an obvious medical origin (obvious trauma or abnormal pulmonary x-rays)
• Had received cognitive-behavior therapy for Panic Disorder in the last six months
• Cognitive impairment preventing the completion of psychological assessment
• Past or present psychotic episode, Bipolar Disorder, or organic mental disorder
• Current Abuse or Dependence Disorder
• If another Mental Disorder is present, its severity was equal or inferior to the severity of Panic Disorder
• Current medical condition preventing the participant from receiving pharmacological of cognitive-behavior treatment

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Universite du Quebec a Montreal Other

Overall Clinical Trial Officials and Contacts

André Marchand, PhD Principal Investigator Universite du Quebec a Montreal  

Overall Contact: André Marchand, PhD 1 (514) 987-3000 marchand.andre@uqam.ca

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00736346

Study ID Number: MOP 81128 (CIHR)

ClinicalTrials.gov Identifier: NCT00736346

Health Authority: Canada: Health Canada